- Home
- SPAI vs KLRS Comparison
SPAI vs KLRS Comparison
Compare SPAI & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPAI | KLRS |
|---|---|---|
| Founded | 2021 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.7M | 92.8M |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SPAI | KLRS |
|---|---|---|
| Price | $4.46 | $3.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $10.00 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 104.9K | 51.6K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.70 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $606,681.00 | $165,000.00 |
| Revenue This Year | $1,060.58 | N/A |
| Revenue Next Year | $162.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.23 | $3.03 |
| 52 Week High | $9.04 | $11.88 |
Technical Indicators
Market Signals| Indicator | SPAI | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 46.17 | 26.00 |
| Support Level | $4.35 | $3.03 |
| Resistance Level | $4.74 | $4.37 |
| Average True Range (ATR) | 0.36 | 0.19 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 19.23 | 2.28 |
Price Performance
Historical ComparisonAbout SPAI Safe Pro Group Inc.
Safe Pro Group Inc operates to acquire security and protection products. The company operated in three reportable business segments, which consisted of the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. The majority of revenue is from Safe-Pro USA.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.